

Journal of Visualized Experiments

Identification of OTX1 and OTX2 as two possible molecular markers for sinonasal carcinomas and olfactory neuroblastomas. --Manuscript Draft--

Article Type:	Methods Article - JoVE Produced Video
Manuscript Number:	JoVE56880R4
Full Title:	Identification of OTX1 and OTX2 as two possible molecular markers for sinonasal carcinomas and olfactory neuroblastomas.
Keywords:	Homeobox genes, sinonasal neoplasms, immunohistochemistry, real-time PCR, tumor markers.
Corresponding Author:	Andrea Conti Universita degli Studi dell'Insubria Varese, VA ITALY
Corresponding Author's Institution:	Universita degli Studi dell'Insubria
Corresponding Author E-Mail:	a.conti3@uninsubria.it
First Author:	Andrea Conti
Other Authors:	Cristina Pirrone
	Alessandro Marando
	Giovanni Micheloni
	Alessia Rainero
	Giorgia Millefanti
	Lucia Tararà
	Andrea Pistochini
	Francesco Lo Curto
	Francesco Pasquali
	Paolo Castelnuovo
	Giovanni Porta
Author Comments:	We submit a revised version of the manuscript taking in consideration the comments provided by the editors and the reviewers. For some questions we are not able to give informations since the reagents used for this work are no more in production.
Additional Information:	
Question	Response
If this article needs to be "in-press" by a certain date, please indicate the date below and explain in your cover letter.	



Università degli Studi dell'Insubria
DMC – DIPARTIMENTO DI MEDICINA E CHIRURGIA
Via J. H. Dunant, 5 – 21100 VARESE, ITALY

Varese, 06/07/2017

To the Editor-in-Chief of Jove

Object: paper submission

On behalf of all co-authors, I would like to submit to the article entitled “Identification of OTX1 and OTX2 as two possible molecular markers for sinonasal carcinomas and olfactory neuroblastomas”.

Our study presents results deriving from immunohistochemical and Real-time PCR investigating OTX1 and OTX2 expression in the more frequent types of nasal and sinonasal tumours. They might have a critical role in the pathogenesis of different types of sinonasal neoplasms

Each of the authors have read and concurs with the contents in the final manuscript.

Hoping the manuscript will meet your positive favor,

Giovanni Porta
University of Insubria
DMC via J.H.Dunant 5,
21100 Varese, Italy
0039-348-7630619 mobile
0039-0332-217106 office
giovanni.porta@uninsubria.it

TITLE:

Identification of OTX1 and OTX2 as Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

AUTHORS & AFFILIATIONS:

Andrea Conti¹, Cristina Pirrone¹, Alessandro Marando², Giovanni Micheloni¹, Alessia Rainero¹, Giorgia Millefanti⁴, Lucia Tararà¹, Andrea Pistochini³, Francesco Lo Curto¹, Francesco Pasquali¹, Paolo Castelnovo³, Giovanni Porta¹.

¹Department of Medicine and Surgery, University of Insubria, Varese, Italy

²Department of Surgical and Morphological Science, University of Insubria, Varese, Italy

³Department of Biotechnology and Life Science, University of Insubria, Varese, Italy

⁴Policlinical of Milan, University of Milan, Milan, Italy

CORRESPONDING AUTHOR:

Andrea Conti

Email Address: andrea.c25@hotmail.it

Tel: +39 333-6501455

EMAIL ADDRESSES OF CO-AUTHORS:

Cristina Pirrone (cristina.pirrone@hotmail.it)

Alessandro Marando (alessandomarando@gmail.com)

Giovanni Micheloni (giovanni.micheloni90@gmail.com)

Alessia Rainero (alessia.rainero@gmail.com)

Giorgia Millefanti (millefantigiorgia@outlook.it)

Lucia Tararà (lucia.tarara@unimi.it)

Andrea Pistochini (andrea.pistochini@uninsubria.it)

Francesco Lo Curto (francesco.locurto@uninsubria.it)

Francesco Pasquali (francesco.pasquali@uninsubria.it)

Paolo Castelnovo (paolo.castelnovo@uninsubria.it)

Giovanni Porta (giovanni.porta@uninsubria.it)

KEYWORDS:

Homeobox genes, sinonasal neoplasms, immunohistochemistry, real-time PCR, tumor, markers

SHORT ABSTRACT:

Homeobox genes are regulatory genes often associated with tumors in the adult organisms. We investigated their comparative expression by immunohistochemical and real-time PCR analysis, in normal and inflammatory nasal mucosae and in sinonasal neoplasms in order to use them as possible diagnostic and therapeutic targets.

LONG ABSTRACT:

OTX homeobox (HB) genes are expressed during embryonic morphogenesis and during the development of olfactory epithelium in adult organisms. Mutations occurring in these genes are

often related to tumorigenesis in human. No data are available today regarding the possible correlation between *OTX* genes and tumors of the nasal cavity. The aim of this work is to understand if *OTX1* and *OTX2* can be considered as molecular markers in the development of nasal tumors. We selected nasal and sinonasal adenocarcinomas to investigate the expression of *OTX1* and *OTX2* genes through immunohistochemical and real-time PCR analyses. Both *OTX1* and *OTX2* were absent in all the samples of sinonasal Intestinal-Type Adenocarcinomas (ITACs). *OTX1* mRNA was identified only in Non-Intestinal Type Adenocarcinomas (NITACs) while *OTX2* mRNA was expressed only in Olfactory Neuroblastomas (ONs). We have demonstrated that the differential gene expression for both *OTX1* and *OTX2* genes might be a useful molecular marker to distinguish the different types of sinonasal tumors.

INTRODUCTION:

OTX HB genes are the vertebrate homologue of the *Drosophila* orthodenticle genes (*otd*) and they encode for transcription factors which are normally expressed during embryonic morphogenesis, but they can also be expressed in the adult organism with different functions. During embryonic development they control the specification of cell identity, cell differentiation, and the positioning of the body axis¹. The *OTX* family includes *OTX1* and *OTX2* genes which display different functions. *OTX1* is involved in brain and sensory organ development. In the adult organism, it is expressed in sensory organs and is transcribed at low levels in the anterior lobe of the pituitary gland²; it also plays a role in hematopoiesis, being expressed in hematopoietic pluripotent and progenitor cells³. *OTX2* is involved in the development of the rostral head and its translated protein acts as a morphogen because it generates a gradient through which other genes are activated or repressed in a spatio-temporal manner, thus contributing to cell proliferation and differentiation. In the adult organism, *OTX2* is found exclusively in the choroid plexus and pineal gland⁴.

Mutations in *OTX* genes are often related to the appearance of human congenital, somatic, or metabolic defects. Gain or loss mutations in *OTX* genes could promote tumorigenesis if they are not able to properly control cellular growth and/or differentiation⁵. In leukemias and lymphomas as well as in many solid tumors (*e.g.*, medulloblastomas⁶, aggressive non-Hodgkin lymphomas², breast carcinomas⁷, colorectal cancers⁸, and retinoblastoma⁹), the deregulated expression of *OTX* HB genes is well documented¹⁰. In addition, *OTX2* mutations have been demonstrated in cases of anophthalmia and microphthalmia¹¹ due to the crucial role for this gene in the control of eye development.

In the context of solid neoplasms, the discovery of molecular and phenotypic markers is an important challenge for the diagnosis, classification, and treatment of several types of tumor¹¹, including those that originate in the nasal cavity and paranasal sinuses. In fact, despite that these areas occupy only a modest anatomical space, mucosal epithelium, glands, soft tissues, bone, cartilage or neural/neuroectodermal, and hematolymphoid cells can be often the site for the origin of complex and histologically different groups of tumors. Different types of neoplasms involving the sinonasal tract present a variety of features that overcome what is usually seen in the upper aerodigestive tract or even throughout most parts of the body¹². Sinonasal malignancies are rare and present an annual incidence of 1:100,000 inhabitants worldwide, and

so this prevents studies regarding the pathways involved in the tumorigenesis and the testing of alternative treatment strategies. Despite this, the advances in imaging techniques, surgical approaches, and radiotherapy have improved the clinical management of sinonasal cancer. Moreover, the development of cell lines as well as animal models and cancer genetic profiling currently constitute the basis for the future targeted anticancer therapies¹³. To date, there are no reports regarding *OTX1* and/or *OTX2* expression in neoplasms of the nasal cavity, paranasal sinuses, and nasopharynx. Since we have previously observed that *OTX1* and *OTX2* are involved in breast cancer⁷, we wondered if these genes could be present not only in the normal nasal mucosa but also in tumors of the nasal cavity. To reach this goal we obtained from the Department of Pathology of the “Ospedale di Circolo” in Varese samples of normal mucosa, and nasal and sinonasal adenocarcinomas collected from 1985 to 2012 and classified according to the World Health Organization (WHO) classification of Head and Neck Tumors. We choose to analyze them through real-time PCR and immunohistochemistry analyses and we evaluated *OTX1* and *OTX2* expression to determine if they can be considered molecular markers for these types of tumors.

PROTOCOL:

All the studies were performed according the Declaration of Helsinki (1975) with written informed consent and approved by the Ethical Committee of the University of Insubria in Varese.

1. Collection of the Samples

1.1. Collect and divide all the human Formalin-Fixed Paraffin-Embedded (FFPE) samples into different subgroups according the WHO classification of Head and Neck Tumors¹⁴.

Note: Here we used the following samples: Normal sinonasal mucosa as control (10 samples); Inverted Papilloma (IP, ICD-O code 8121/1); Sinonasal ITAC (ICD-O code 8144/3, 32 samples); NITAC (ICD-O code 8140/3, 12 samples); Adenoid Cystic Carcinoma (ACC, ICD-O code 8200/3); Pleomorphic Adenoma (PA, ICD-O code 8941/3); ON (ICD-O code 9522/3, 13 samples); Poorly Differentiated Neuroendocrine Carcinoma (PDNEC, ICD-O code 8041/3, 19 samples); Neuroendocrine Tumor (NET, ICD-O code 8041/3).

2. Immunohistochemistry

2.1. Deparaffinization and rehydration of sections

2.1.1. Heat the sample slides in an oven at 60 °C for 30 min and rehydrate 3 µm thick FFPE sections using an alcohol series to water.

2.1.2. Briefly wash the slides in xylene for 10 min and repeat this step; wash the slides for 5 min in 100% alcohol and repeat this step using 95%, 85%, and 75% alcohol serially. Rinse the slides for 5 min in distilled water.

2.2. Blocking the endogenous activity

2.2.1. Block the endogenous activity by placing the slides in 3% aqueous hydrogen peroxide for 12 min.

2.3. Antigen retrieval

2.3.1. Perform antigen retrieval by treating with 10 mM Citrate Buffer (pH 6) for 10 min in a microwave treatment.

2.4. Incubation with primary antibody

2.4.1. Wash the sections in TBS buffer (pH 7.4), add 0.2% of Triton X, and incubate overnight at 4 °C with goat anti-human OTX2 antibody diluted 1:100.

2.5. Incubation with secondary antibody

2.5.1. Incubate the sections for 1 h at room temperature with biotinylated rabbit anti-goat secondary antibody diluted 1:200 followed by ABC-peroxidase complex (see **Tables of Materials**).

2.6. Developing the immunoreaction

2.6.1. Develop the immunoreaction using 3,3'-diaminobenzidine tetrahydrochloride and counterstain the nuclei with Harris Hematoxylin.

2.7. Mounting and imaging

2.7.1. Dehydrate the sections using a crescent alcohol-scale and clarify them using a clearing substance of terpene origin (see **Table of Materials**). Embed sections in mounting medium, place the sections on a microscope slide, and observe the sections through an optical microscope.

3. RNA Extraction and Reverse-transcription

3.1. RNA extraction

3.1.1. Extract RNA from the sections by performing the first step of immunoprecipitation protocol (see section 2.1) and keep the slides in distilled water. Overlap the unstained sections with the corresponding hematoxylin-eosin stained sections in order to identify fragments of interest.

3.1.2. Perform the RNA extraction using a commercial RNA extraction kit for FFPE samples (see **Table of Materials**) and following manufacturer's instructions.

3.2. RNA reverse-transcription

3.2.1. Use a commercial kit to retro-transcribe RNA into cDNA (see **Table of Materials**) following the protocol. Retro-transcribe at least 1,000 ng of total RNA to perform several analyses.

4. Real-time PCR and Data Analysis

4.1. Real-time PCR

4.1.1. Perform quantitative real-time PCR analyses (qRT-PCR) with probe-based technology (see **Table of Materials**) and a thermal cycler.

4.2. Preparation of the PCR reaction mix

4.2.1. Prepare the PCR reaction mix using 12.5 µL of probe-based master mix, 1.25 µL each of OTX1, OTX2, and ACTB probes (see **Table of Materials**), 50 ng of cDNA, and nuclease-free water up to 25 µL of total volume.

4.2.2. Perform all the reactions in triplicate using the ACTB gene as the endogenous control to normalize gene expression levels.

4.2.3. Centrifuge the plate at 1,109 x g for 3 min and store the plate protected from light at 4 °C until the experiment.

4.3. Setting the thermal cycler

4.3.1. Set the thermal cycler profile with an initial hot start cycle at 50 °C for 2 min and 90 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and a final cycle at 60 °C for 1 min.

4.4. Gene expression level analyses

4.4.1. Normalize the gene expression levels through the comparative cycle threshold (ΔC_t) method using the ACTB gene as the endogenous control.

4.4.2. Evaluate gene expression levels using the $2^{-\Delta C_t}$ method and plot the results.

4.5. Statistical analyses

4.5.1. Perform statistical analyses using Student's *t*-Test, considering statistically significant results with $p < 0.05$.

REPRESENTATIVE RESULTS:

In the normal mucosa we observed strong and homogenous nuclear reactivity for OTX genes both in the ciliated pseudostratified respiratory-type epithelium and in the submucosal glandular cells (**Figure 1A**). We found nuclear expression for OTX1 in all NITACs samples (**Figure 1B**), while little or absent immunoreactivity was highlighted in ITACs (**Figure 1C**). Intense immunoreactivity was

present in all ONs (**Figure 1D**); among PDNECs, OTX expression varied in intensity and percentage of positive cells (**Figure 1E**). Immunohistochemical statistical analysis performed with Chi square and/or Fisher's exact test demonstrated that the absence of OTX genes in ITAC samples was statistically significant ($n = 23$, $p < 0.01$).

Real-time PCR analyses confirmed the expression of both OTX1 and OTX2 genes in control samples (**Figure 2A–B**); OTX1 but not OTX2 was expressed in NITAC samples and both genes were completely downregulated in ITACs (**Figure 2A–B**). In ON samples we found only the expression of OTX2 gene while OTX1 was downregulated, and among the PDNEC samples the expression of both genes varied (**Figure 2A–B**).

Student's *t* test performed on real-time PCR confirmed statistically significant data for *OTX1* in controls vs. ITACs ($n = 9$, $p < 0.05$), controls vs. ONs ($n = 6$, $p < 0.05$), controls vs. PDNECs ($n = 8$, $p < 0.05$), and for *OTX2* in control vs. NITACs ($n = 5$, $p < 0.05$), controls vs. ITACs ($n = 9$, $p < 0.05$), controls vs. ONs ($n = 6$, $p < 0.05$), and controls vs. PDNECs ($n = 8$, $p < 0.05$).

FIGURE LEGENDS:

Figure 1. Representative images of OTX immunohistochemical expression in control and neoplastic tissues. The reaction developed by the peroxidase-conjugated secondary antibody revealed the signal (dark brown) was visible in 5 control FFPE sections of normal sinonasal mucosa (**A**), 7 cases of Non-intestinal-type adenocarcinomas (NITACs) (**B**), 7 cases Olfactory neuroblastomas (ONs) (**D**), 11 cases Poorly differentiated neuroendocrine carcinomas (PDNECs) (**E**), while no immunoreactivity is detected in the 23 cases of Intestinal-type adenocarcinomas (ITACs) analyzed (**C**). DAB-Hematoxylin; original magnification: 200X, scale bar = 100 μ m.

Figure 2. Real-time PCR analysis of OTX1 (A) and OTX2 (B) mRNA expression in normal and neoplastic nasal tissues. For real-time PCR analyses, the following samples were used: 5 FFPE sections of control normal mucosa, 5 cases of Non-intestinal-type adenocarcinomas (NITACs), 9 cases of Intestinal-type adenocarcinomas (ITACs), 6 cases of olfactory neuroblastomas (ONs), 8 cases of Poorly differentiated neuroendocrine carcinomas (PDNEC). On the X axis the type of sample is reported, while the Y axis represents the $2^{-\Delta Ct}$ values. Statistically significant data ($p < 0.05$) between control and tumors were obtained by Student's *t*-test and are highlighted with asterisks.

DISCUSSION:

This study shows for the first time that, based on mRNA levels, the HB genes OTX1 and OTX2 are expressed in normal sinonasal mucosa and submucosal glands, inflammatory polyps, sinonasal Schneiderian papillomas, and in the different epithelial and neuroectodermal neoplasms, including squamous carcinomas, non-intestinal type sinonasal adenocarcinomas, salivary gland-type tumors, neuroendocrine neoplasms, and ONs.

Modifications and Troubleshooting:

To avoid RNA degradation, we performed the deparaffinization protocol in the Laboratory of

Pathology. After we scratched the slides, all the samples were rapidly cooled and stored in dry ice until further use. We performed all the subsequent analyses in a laminar-flow safety hood using a dedicated set of pipettes with sterile tips to maintain aseptic experimental conditions and to avoid RNA contaminations.

Limitations of the Technique:

The principal limitation of the technique relies on the availability of samples since tumors of sinonasal cavity are often rare. The amount of extracted RNA is another important issue because RNA extraction from FFPE samples results in fragmented RNA which is difficult to analyze.

Significance with Respect to Existing Methods:

The diagnosis of tumors of the nasal cavity usually consists of X-rays analyses, endoscopic exam of the nasal cavity, CT scan, magnetic resonance (RMN), and biopsy. During the recent years, the advances of surgical instrumentation and the progress of imaging techniques had led endoscopic surgery as the preferred strategy for sinonasal tumors. Notably, this technique has been reported as feasible for different benign or malignant types of sinonasal tumors¹⁵. Our technique based on qRT-PCR allows the identification of molecular biomarkers, which can differentially discriminate samples of different tumors: in fact, we provide evidence that the absence of both the HB genes in ITACs can be used as molecular markers for this type of tumor as well as the absence of OTX2 in NITACs. Moreover, this technique can be applied immediately after the biopsy and can give definitive results in less than 6 hours with respect to the days or weeks necessary for the report from the hospital.

Future Applications:

Our future studies involve analyzing gene and protein expression levels of OTX1 and OTX2 HB genes using real time PCR analyses, Western blot, and immunofluorescence with specific antibodies to detect not only OTX1 and OTX2, but also p53 family expression levels. Since we previously demonstrated that OTX1 expression is regulated by p53 in breast cancer⁷, it would be interesting to understand if such a regulation exists also in nasal cavity tumors. An immunofluorescence assay and a Chromatin Immunoprecipitation (ChiP) assay can reveal, respectively, a protein-protein and a DNA-protein interaction between p53 and OTXs. If such a connection is found, the targeted silencing of p53 (and the family members, p63 and p73), will reveal if the over-expression or down-regulation of OTX genes is dependent on p53.

p53 loss of function, through mutation in p53 itself or perturbations in pathways signaling to p53, is a common feature in the majority of human cancers¹⁶. Most of the p53 mutations cluster within the DNA-binding domain; therefore, DNA-binding activity is the critical function that is altered, suggesting that changes in transcriptional genes could be the key to mutant p53 activity¹⁶. p53 mutations have been reported as a common feature of sinonasal cancer, with an overall frequency of 77%, and they show association to adenocarcinoma and wood-dust exposure¹⁷. Thus, in our samples, it would be interesting to evaluate mRNA and protein levels (by qR-PCR and Western Blot analysis) and to perform the sequencing of this gene, in order to identify or exclude the presence of activating/inactivating mutations. Finally, if a tumor-type specific recurrent mutation is found, it would be noteworthy to produce engineered cells and mice (with one

mutant allele) that harbor this mutation, and examine if the mutation can recapitulate the disease.

Critical Steps:

Critical steps of this study include the obtainment of well-stored samples, either as biopsies stored in RNA protective buffer or FFPE samples of at least 8 µm thick, and the extraction of at least 200 ng of RNA to perform qRT-PCR analyses.

ACKNOWLEDGMENTS:

This work was supported by Centro Grandi Strumenti Università dell'Insubria, Fondazione Comunitaria del Varesotto, Fondazione del Monte di Lombardia, and Fondazione Anna Villa e Felice Rusconi.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

1. Boncinelli, E., Simeone, A., Acampora, D., Gulisano, M. Homeobox genes in the developing central nervous system. *Ann genet.* **36** (1), 30-37 (1993)
2. Omodei, D. et Al. Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-centre B cells and in aggressive Non-Hodgkin lymphoma. *American J. Pathol.* **175**, 2609-2617 (2009).
3. Levantini, E. et al. Unsuspected role of the brain morphogenetic gene OTX1 in haematopoiesis. *Proc. Natl. Acad. Sci USA* **100** (18), 10299-10303 (2003).
4. Larsen, K.B., Lutterodt M.C., Mollgard, K., Moller, M. Expression of the homeobox OTX2 and OTX1 in the early developing human brain. *J. Histochem. Cytochem.* **58**, 669-678 (2010)
5. Abate-Shen, C. Deregulated homeobox gene expression in cancer: cause or consequence? *Nat. Rev. Cancer* **2**, 777-785 (2002).
6. De Haas, et al. OTX1 e OTX2 expression correlates with the clinicopathologic classification of medulloblastoma. *J. Neuropathol. Exp. Neurol.* **65**, 176-186 (2006).
7. Terrinoni, A. et al. OTX1 expression in breast cancer is regulated by p53. *Oncogene* **30** (27), 3096-3103 (2001).
8. Yu, K., et al. OTX1 promotes colorectal cancer progression through epithelial-mesenchymal transition. *Biochem. Biophys Res Commun.* **44** (1), 1-5 (2014).
9. Glubrecht, D.D., Kim, J.H., Russel, L., Bamforth, J.S., Godbout, R. Differential CRX and OTX2 expression in human retina and retinoblastoma. *J. Neurochem.* **111**(1), 250-263 (2009).
10. Coletta R.D., Jedlicka, P., Gutierrez-Hartamn, A., Ford H.L. Transcriptional control of the cell cycle in mammary gland development and tumorigenesis. *J. mammary gland Biol. Neoplasia*, **9**, 39-53 (2004).
11. Cordes, B. et al. Molecular and phenotypic analysis of poorly differentiated sinonasal neoplasms: an integrated approach for early diagnosis and classification. *Hum Pathol.* **40**, 283-292 (2009).
12. Stelow, E.B. and Bishop J.A. "Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Nasal Cavity, Paranasal

Sinuses and Skull Base." *Head Neck Pathol.* **11**(1):3-15 (2017).






13. Llorente, J.L. et al. "Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances." *Nat. Rev. Clin. Oncol.* **11**(8):460-72. (2014).



14. Sidransky D. World health organization classification of tumors. Pathology and genetics of head and neck tumors, vol.9. WHO Press, 2005.

15. Radulesku, T. et al. "Endoscopic surgery for sinonasal tumors: The transcribriiform approach." *J Stomatol Oral Maxillofac Surg.* **118**(4):248-250 (2017).

16. Muller, P.A.J., Vousden, K.H. p53 mutations in cancer. *Nature cell biology*, **15**(1), 2-8 (2013).

17. Holmila, R. et al. Profile of TP53 gene mutations in sinonasal cancer. *Mutat Res.* **686** (1-2), 9-14 (2010).



A**B**

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
RecoverAll Total Nucleic Acid Isolation	Applied Biosystem	AM1975	Out of production. Sequence protected by copyright Out of production. Sequence protected by copyright Out of production. Sequence protected by copyright
High-Capacity cDNA Reverse Transcription Kit	Applied Biosystem	4368814	
TaqMan Universal PCR Master Mix, no AmpErase UNG	Applied Biosystem	4326614	
ABI Prism 7000	Applied Biosystem	270001857	
ACTB probe	Applied Biosystem		
OTX1 probe	Applied Biosystem		
OTX2 probe	Applied Biosystem		
Acqueous Hydrogen Peroxide	Merk	1072090250	
Citrate Buffer	Sigma-Aldrich	20276292	
Triton	Sigma-Aldrich	101473728	
Tris	Merk	108382	Out of production. Catalog number not available
NaCl	Merk	106404	
Goat Anti-OTX2 Antibody	Vector Laboratories		
Rabbit Anti-Goat Antibody	Vector Laboratories	BA5000	
ABC-Peroxidase Complex	Vector Laboratories	PK6100	
3,3'-diaminobenzidine tetrahydrochloride (DAB)	Sigma-Aldrich	D5905	
Harris Hematoxylin	Bioptica	0506004/L	
Pertek	Kaltek SRL	1560	
BioClear	Bioptica	W01030799	



1 Alewife Center #200
 Cambridge, MA 02140
 tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Identification of OTX1 and OTX2 as two possible molecular markers for sinonasal carcinomas and olfactory neuroblastomas

Author(s):

Andrea Conti, Cristina Pirrone, Anna M. Chiaravalli, Alessandro Marando, Giovanni Micheloni, Alessia Rainero, Andrea Pistochini, Francesco Lo Curto, Francesco Pasquali, Paolo Castelnovo, Carlo Capella, Giovanni Porta

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's


expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:	Andrea Conti	
Department:	Department of Medicine and Surgery	
Institution:	University of Insubria, Varese (VA, Italy)	
Article Title:	Identification of OTX1 and OTX2 as two possible molecular markers for sinonasal carcinomas and olfactory neuroblastomas	
Signature:		Date: 06/07/2017

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Dear Dr Conti,

Thank you for your JoVE submission, JoVE56880 Identification of OTX1 and OTX2 as two possible molecular markers for sinonasal carcinomas and olfactory neuroblastomas.. After careful consideration, we cannot proceed with your submission because it does not follow our instructions for authors (which can be found [here](#)). Thus, we cannot accept your submission in its current form.

For your guidance, specific comments from our editorial team include but are not limited to the following:

Parts of the manuscript have significant textual overlap with previous publication(s), including, possibly, the authors' own. All text must be original. Please fully rewrite the text in red font in the attached document to avoid this overlap. We require the protocol to be presented using stepwise details in the imperative voice, please keep this in mind as you re-write the Protocol section (see Author guidelines [here](#)).

Please contact us if you have any questions regarding the revisions required to proceed with your submission. To resubmit a revised manuscript, go to the [JoVE submission site](#) and log in as an author. You will find your submission under the heading 'Submission Needing Revision'.

Thank you for giving us the opportunity to consider your work.

Sincerely,

Alisha DSouza, Ph.D.

Review Editor

[JoVE](#)

617.674.1888

Follow us: [Facebook](#) | [Twitter](#) | [LinkedIn](#)

[About JoVE](#)

Pavia, 15 September 2017

Dr. Andrea Conti
Department of Medicine and Surgery
Laboratory of Molecular Genetics
University of Insubria
via J.H. Dunant 5
21100 Varese
Italy


Dear Dr. Conti,

thank you for your request to use the images of your scientific paper "**OTX1 and OTX2 as possible molecular markers of sinonasal carcinomas and olfactory neuroblastomas**", by C. Pirrone, A.M. Chiaravalli, A. Marando et al. (2016) *Eur J Histochem* 61(1):2730 for an article to be published.

As the paper is an open-access article licensed under a Creative Commons Attribution NonCommercial 4.0 License ([CC BYNC 4.0](#)), the use, distribution or reproduction in appropriate forums is permitted, provided that the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice.

No use, distribution or reproduction is permitted which does not comply with these terms.

Best regards,



Nadia Moscato

Head of the Journal Division
PAGEPress srl
Scientific Publications